JPRN-jRCT2080223435已完成1 期
An Open-Label Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Subjects With Selected Solid Tumors
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 6
研究概览
简要总结
The combination of lenvatinib 20 mg plus pembrolizumab 200 mg was well tolerated and safe in subjects with selected solid tumors. The efficacy results showed that the combination of lenvatinib plus pembrolizumab provided antitumor activity in subjects with selected solid tumors.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •(1)Histologically and/or cytologically confirmed selected solid tumor types.
- •The selected tumor types are: non-small cell lung cancer, predominantly clear cell renal cell carcinoma, endometrial carcinoma, urothelial carcinoma, squamous cell carcinoma of the head and neck, or melanoma (excluding uveal melanoma)
- •(2)At least 1 measurable target lesion
- •(3)Participants must have an Eastern Cooperative Oncology Group (ECOG)-Performance Status (PS) of 0 to 1.
- •(4)Adequately controlled blood pressure .
- •(5)Adequate renal function
- •(6)Adequate bone marrow function:
- •(7)Adequate blood coagulation function
- •(8)Adequate liver function
- •(9)Life expectancy of 12 weeks or more
排除标准
- •(1)Prior anticancer treatment within 28 days (or 5 times the half-life time, whichever is shorter) or any investigational agent within 28 days prior to the first dose of study drugs.
- •(2)Biologic response modifiers within 4 weeks before study entry.
- •(3)Participants having >=2+ proteinuria on urinalysis will undergo 24-hour urine collection for quantitative assessment of proteinuria.
- •(4)Prolongation of QTc (Fridericia formula) interval to >480 milliseconds (ms)
- •(5)Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to the first dose of study drug.
- •(6)Active infection (any infection requiring systemic treatment)
- •(7)Participant is known to be positive for Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C
- •(8)History of organ allograft.
- •(9)Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment.
- •(10)Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis, or has a history of interstitial lung disease.
- •(11)Has received a live-virus vaccination within 30 days of planned treatment start.
- •(12)Females who are breastfeeding or pregnant.
研究者
相似试验
已完成
2 期
Lenvatinib and Pembrolizumab Simultaneous Combination StudyAdvanced Gastric CancerNCT03609359National Cancer Center Hospital East29
已完成
1 期
Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid TumorsSolid TumorsNCT03006887Eisai Co., Ltd.6
已完成
1 期
A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular CarcinomaHepatocellular CarcinomaNCT03006926Eisai Co., Ltd.104
已完成
1 期
An Open-Label Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular CarcinomaHepatocellular CarcinomaJPRN-jRCT2080223439Eisai Co., Ltd.104
已完成
1 期
A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid TumorsTumorsNCT02501096Eisai Inc.357